The numbers were small, in part because people with heart disease had been screened out of the trial, but the trend had been worrisome and the latest data were striking: After 18 months on the drug, the Vioxx group was clearly having more heart problems than the placebo group and the rate of difference was accelerating.
The painkillers known as COX-2 inhibitors, which include Bextra and Vioxx, have been widely prescribed to people suffering with arthritis.
Vioxx was Merck's fourth top seller, and they knew their decision would be extremely harmful to the company.